What Cannabics Pharmaceuticals does

Cannabics Pharmaceuticals (legal entity Cannabics Inc., operating as CNBX Pharmaceuticals) is a pre-revenue, publicly traded pharmaceutical R&D company founded in 2012 and headquartered in Bethesda, Maryland. The company is developing cannabinoid-based therapeutic drug candidates for oncology and neuropsychiatric indications, with a stated mission to be a global leader in cannabinoid-molecule-based cancer therapeutics. Its lead asset, CNBX RCC-33, is positioned as the world's first cannabinoid-based antitumor drug candidate for colorectal cancer. The broader pipeline includes formulations targeting pre-cancerous polyps, melanoma, breast cancer, and prostate cancer, plus two neuropsychiatric candidates (NP-01 and NP-02).

The company's underlying technology is a proprietary High Throughput Screening (HTS) platform paired with advanced bioinformatics, operated from in-house drug discovery facilities. This platform screens cannabinoid formulations against cancer cells to identify and optimize proprietary therapeutic candidates. Core technical differentiators include the novel RCC-33 formulation architecture and the in-house HTS capability, which the company claims enables rapid screening and candidate development.

Cannabics has no commercial products, no disclosed customers, and no pricing model. Its revenue model is characterized in the source as contingent on successful clinical trials and regulatory approvals, with potential future revenue via one-time licensing arrangements. The company is currently funded at a modest level, with only one disclosed capital event (a $3.0 million round in May 2017) and a 1-10 employee headcount. Go-to-market motion is undeveloped; the company relies on social media, a newsroom, an investor relations website, and email newsletters to communicate with stakeholders.

Name

Cannabics Pharmaceuticals

Legal name

Cannabics Inc.

Website

https://cannabics.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

Cannabics Pharmaceuticals is a pre-revenue, publicly traded R&D company developing cannabinoid-based therapeutic drug candidates for multiple cancers and neuropsychiatric conditions, using a proprietary High Throughput Screening platform. Its lead candidate, CNBX RCC-33, targets colorectal cancer.

Ownership category

akta.pro rank

Product category

Cannabinoid-based Oncology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)

akta.pro secondary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Cannabinoid drug development
• Antitumor therapeutics
• Oncology pharmaceutical research
• Neuropsychiatric drug candidates
• High throughput screening

Headquarters

HQ city

Bethesda

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Pre-revenue / R&D Stage: Cannabics Pharmaceuticals is a pre-revenue pharmaceutical company in the research and development phase. The company is developing cannabinoid-based drug candidates for cancer treatment and neuropsychiatric conditions. Revenue generation is contingent on successful clinical trials and regulatory approvals.

Marketing channels7 records

Core offering

Cannabics Pharmaceuticals develops proprietary cannabinoid-based therapeutic drug candidates targeting multiple cancer types and neuropsychiatric conditions. Its flagship candidate, CNBX RCC-33, is positioned as the world's first cannabinoid-based antitumor drug candidate for colorectal cancer, with additional candidates addressing melanoma, breast cancer, prostate cancer, and pre-cancerous polyps, as well as neuropsychiatric drug candidates NP-01 and NP-02. All candidates are produced through in-house drug discovery using proprietary High Throughput Screening (HTS) technology and advanced bioinformatics.

Product overview

Cannabics Pharmaceuticals is a pharmaceutical development company with a portfolio of cannabinoid-based therapeutic drug candidates. The core offering consists of CNBX RCC-33 (the world's first cannabinoid-based antitumor drug for colorectal cancer) along with additional cancer treatments including formulations for melanoma, breast cancer, prostate cancer, and pre-cancerous polyps. The company also develops neuropsychiatric drug candidates (NP-01, NP-02). All candidates are developed using the company's proprietary Drug Discovery Platform featuring High Throughput Screening (HTS) technology and advanced bioinformatics. The company operates in-house state-of-the-art drug discovery facilities and was established in 2012.

Differentiator

Problem solved

Functional benefit

Products and services

• CNBX RCC-33 The company's flagship cannabinoid-based antitumor drug candidate for the treatment of colorectal cancer, based on a novel and proprietary formulation; positioned as the world's first cannabinoid-based antitumor drug candidate.
• Pre-cancerous Polyps Treatment Cannabinoid-based therapeutic formulation targeting pre-cancerous polyps as part of the company's colorectal cancer-related drug development program.
• Melanoma Treatment Cannabinoid-based therapeutic drug candidate targeting melanoma skin cancer, part of the company's additional cancer program.
• Breast Cancer Treatment Cannabinoid-based therapeutic drug candidate targeting breast cancer, part of the company's additional cancer program.
• Prostate Cancer Treatment Cannabinoid-based therapeutic drug candidate targeting prostate cancer, part of the company's additional cancer program.
• NP-01 Neuropsychiatric drug candidate based on cannabinoid molecules, addressing unmet medical needs in neuropsychiatric treatment.
• NP-02 Neuropsychiatric drug candidate based on cannabinoid molecules, addressing unmet medical needs in neuropsychiatric treatment.
• Drug Discovery Platform In-house state-of-the-art drug discovery platform using proprietary High Throughput Screening (HTS) technology and advanced bioinformatics to screen and develop cannabinoid-based therapeutic formulations, including the CNBX RCC-33 candidate and other cancer and neuropsychiatric programs.

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Tilray Brands: Large cannabis company with pharmaceutical division pursuing cannabinoid-based therapeutics globally. Comparable as a broad cannabis-pharma incumbent with much greater resources than CNBX.
• Jazz Pharmaceuticals: Acquired GW Pharmaceuticals in 2021, gaining FDA-approved Epidiolex (cannabidiol). Relevant as the established incumbent in cannabinoid pharma with the resources and regulatory expertise that smaller players like CNBX lack.
• Canopy Growth: Diversified cannabis company with pharmaceutical-grade cannabinoid operations and clinical research programs. Comparable as a broad incumbent in cannabinoid drug development with significantly greater capital base.
• Cronos Group: Global cannabinoid company with pharmaceutical research initiatives including cannabinoid-derived therapeutics. Comparable as a broad cannabis-pharma player though focused more on consumer products than oncology drug development.

Direct peers

• InMed Pharmaceuticals: Clinical-stage pharmaceutical company developing cannabinoid-based therapeutics for diseases with high unmet medical need. Comparable as a small-cap cannabinoid pharma pursuing FDA-style drug development with multiple pipeline candidates.
• Tetra Bio-Pharma: Cannabinoid-derived therapeutic drug development company focused on oncology and rare diseases. Directly comparable in cannabinoid-pharma R&D approach and indication overlap with CNBX.
• Cardiol Therapeutics: Clinical-stage cannabinoid pharmaceutical company developing therapies for inflammatory heart disease. Comparable as a small public cannabinoid pharma pursuing FDA-regulated drug development.
• Zynerba Pharmaceuticals: Develops proprietary cannabinoid therapeutics delivered through the skin for CNS conditions. Comparable cannabinoid-pharma R&D model targeting neuropsychiatric indications like CNBX's NP-01/NP-02.

Emerging players

• Sirona Biochem: Biotech company developing proprietary drug candidates including cannabinoid-based compounds using proprietary chemistry platform. Comparable as a small-cap drug discovery company leveraging proprietary platform technology.
• Corbus Pharmaceuticals: Clinical-stage pharmaceutical company focused on oncology and rare diseases with proprietary drug platforms. Comparable as a small-cap pharma with a diversified pipeline of proprietary candidates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xx.com/cannabics1
• Facebookfacebook.com/CNBXPharma
• LinkedInlinkedin.com/company/cannabics-inc-
• Instagraminstagram.com/cnbxpharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cannabics Pharmaceuticals